Eventide Asset Management, LLC Nurix Therapeutics, Inc. Transaction History

Eventide Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $5.64 Million - $10.6 Million	-716,000 Reduced 38.29%	1,154,000 $14.6 Million
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $17.7 Million - $23.1 Million	670,000 Added 55.83%	1,870,000 $54.1 Million
Q1 2021 May 14, 2021	BUY	$26.98 - $50.17 $4.05 Million - $7.53 Million	150,000 Added 14.29%	1,200,000 $37.3 Million
Q4 2020 Feb 16, 2021	BUY	$22.85 - $48.44 $12.6 Million - $26.8 Million	552,260 Added 110.95%	1,050,000 $34.5 Million
Q3 2020 Nov 13, 2020	BUY	$16.05 - $34.91 $7.99 Million - $17.4 Million	497,740 New	497,740 $17.4 Million

180

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $860M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.